Lead storyLead story · #earnings
Pfizer raises its outlook, but COVID sales still drag
Pfizer lifts 2026 guidance as non-COVID sales grow 7% operationally, while total Q3 revenue is nearly flat. The timed stock reaction, peer context and November 6 dividend risks for option sellers.







